# EVALUATION OF AVOIDED COST IN CLINICAL TRIALS WITH MMUNOTHERAPY IN LUNG CANCER

Escobar Hernández L[1]*, Ballesta López O[1], Megias Vericat JE[1], Palanques Pastor T[1], Benito Zazo N[1], Moreno M[1], Tordera Baviera M[1], Poveda Andrés JL[1]

[1]*Servicio de Farmacia, Hospital Universitari i Politecnic La Fe, Valencia. (Spain)*

*corresponding author: escobar_luc@gva.es

***Abstract number: 4CPS-070***
***ATC code :L01- ANTINEOPLASTIC AGENTS***

## Background and objectives

A large number of immunotherapy-based clinical trials (CT) are currently underway for lung cancer (LC). Therefore, it is necessary to evaluate the economic impact of CT in LC patients.

The **main objetive** was to evaluate the **economic impact of participating in CT with immunotherapy provided by the sponsor** in patients with LC**.**

## Material and methods

- ✓ **Design**: Single-center multidisciplinary study in a tertiary hospital between January2019-December2022.
- ✓ **Inclusion criteria:** Patients diagnosed with LC (small cell and non-small cell) treated with commercialized immunotherapy in CT (amivantamab, atezolizumab, avelumab, durvalumab, ipilimumab, nivolumab and pembrolizumab).
- ✓ **Data analyzed**: Baseline characteristics (age and sex), diagnosis, clinical data (trials per phase and drug administered) and consumption data (quantity expressed in mg and costs avoided per CT, per patient and per diagnosis).
- ✓ **Statistical analysis**: calculation of percentages and means with 95% confidence intervals (95%CI). Economic data was expressed in avoided costs.

## Results

- ✓ 81 patients (71.6% male)
- ✓ Average age: 65.7 years (95%CI:63.8-67.6).
- ✓ Most of them diagnosed with non-small-cell LC (85.2%, n=69)

- ✓ The **overall avoided cost** was 2,178,167€ (1,715,360€ and 462,807€ for non-small cell lung cancer and small cell lung cancer, respectively),
- ✓ The avoided cost per CT was 80,673€ and per patient 26,891€.

**CT PER PHASE**




**CT PER DRUG**




## Conclusion and relevance

Patient participation in CT with immunotherapy in LC has a **great economic** impact in terms of **direct costs avoided in antineoplastic treatment**. The inclusion of patients in these CT contributes to the sustainability of the healthcare system and allows patients access to innovative therapies.